regavirumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 464380525

| image =

| type = mab

| mab_type = mab

| source = u

| target = cytomegalovirus glycoprotein B

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 153101-26-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = STG2Q92FWF

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG = D09852

| chemical_formula =

| molecular_weight =

}}

Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.{{cite journal | vauthors = Arizono H, Sugano T, Kaida S, Shibusawa K, Karasawa Y, Esumi Y, Kondo S, Kiyoki M | display-authors = 6 | title = Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys | journal = Arzneimittel-Forschung | volume = 44 | issue = 7 | pages = 909–13 | date = July 1994 | pmid = 7945531 }}